E-LIB Suche - Ergebnisse für: Martinez‐Calle, N.

1

EPIC: A NON‐INTERVENTIONAL, OBSERVATIONAL UK STUDY OF CHRON..:

Eyre, T. A. ; Martinez‐Calle, N. ; Walewska, R....
Hematological Oncology. 41 (2023) S2 - p. 737-738 , 2023

Link: https://doi.org/10.1002/..

2

Replacing procarbazine with dacarbazine in escalated BEACOP..:

Santarsieri, A. ; Mitchell, E. ; Sanghvi, R....
Hematological Oncology. 41 (2023) S2 - p. 356-357 , 2023

Link: https://doi.org/10.1002/..

3

POPULATION‐BASED COHORT STUDY OF THE EFFICACY OF BRENTUXIMA..:

Halligan, S. ; Grainge, M. J. ; Martinez‐Calle, N...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

4

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITU..:

Santarsieri, A. ; Sturgess, K. ; Brice, P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

5

REAL WORLD OUTCOMES AND RESPONSES TO SECOND‐LINE THERAPY IN..:

Shotton, R. ; Kirkwood, A. A. ; Northend, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

6

Safety and effectiveness of a prothrombin complex concentra..:

Marcos‐Jubilar, M. ; García Erce, J. A. ; Martínez‐Calle, N....
Transfusion Medicine. 29 (2019) 4 - p. 268-274 , 2019

Link: https://doi.org/10.1111/..

7

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE / PROCAR..:

Follows, G. ; Santarsieri, A. ; Sturgess, K....
Hematological Oncology. 37 (2019) S2 - p. 490-491 , 2019

Link: https://doi.org/10.1002/..

8

Impact of intended and relative dose intensity of R‐CHOP in..:

Eyre, T. A. ; Martinez‐Calle, N. ; Hildyard, C....
Journal of Internal Medicine. 285 (2019) 6 - p. 681-692 , 2019

Link: https://doi.org/10.1111/..

9

The evolving use of measurable residual disease in chronic ..:

Fisher, A. ; Goradia, H. ; Martinez-Calle, N...
Frontiers in Oncology. 13 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

10

C0374: Venous Thromboembolism in Hospitalised Cancer Patien..:

Lecumberri, R. ; Alfonso, A. ; Marqués, M....
Thrombosis Research. 133 (2014) - p. S4-S5 , 2014

Link: https://doi.org/10.1016/..

11

Allogeneic hematopoietic stem cell transplantation outcome ..:

Anantharachagan, A ; Loh, SY ; Burns, SO...
https://discovery.ucl.ac.uk/id/eprint/10184801/1/1-s2.0-S2772829323001169-main.pdf. , 2024

Link: https://discovery.ucl.ac..

12

The evolving use of measurable residual disease in chronic ..:

Fisher, A ; Goradia, H ; Martinez-Calle, N..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992794/. , 2023

Link: http://www.ncbi.nlm.nih...

13

Impact of MYC and BCL2 Double Expression on Outcomes in Pri..:

Poynton, E ; Chernucha, E ; Day, J...
2152-2650. , 2023

Link: https://qmro.qmul.ac.uk/..

14

The evolving use of measurable residual disease in chronic ..:

A. Fisher ; H. Goradia ; N. Martinez-Calle..
https://www.frontiersin.org/articles/10.3389/fonc.2023.1130617/full. , 2023

Link: https://doi.org/10.3389/..

15

International multicenter retrospective analysis of thiotep..:

Khwaja J ; Kirkwood A. A ; Isbell L. K...
info:eu-repo/semantics/altIdentifier/pmid/36300776. , 2023

Link: https://hdl.handle.net/2..